What is the dosage of Erbitux?

Erbitux is available in 2 dosages, including 2 mg/ml Injection 50 ml and 2 mg/ml Injection 100 ml

What is Erbitux mechanism of action?

Erbitux mechanism of action is HER1 Antagonists

Erbitux Prescribing & Dosing Schedule

Q: What does Erbitux treat?

Erbitux treats Carcinoma, Squamous Cell

Q: What is Erbitux made of?

Erbitux contains cetuximab which is a Epidermal Growth Factor Receptor Antagonist

Q: How is Erbitux administered?

Erbitux is administered as a Injectable

Last Update: Oct, 05 2024

Erbitux(cetuximab)

Erbitux 100 MG in 50 ML Injection

BOXED WARNING

Dosage & Administration

* Premedicate with an H1 receptor antagonist.
* In Combination With Radiation Therapy:
* Initial dose: 400 mg/m2 administered as a 120-minute intravenous infusion one week prior to initiating a course of radiation therapy.
* Subsequent doses: 250 mg/m2 administered as a 60-minute infusion every week for the duration of radiation therapy (6–7 weeks).
* Complete ERBITUX administration 1 hour prior to radiation therapy.

* As Single-Agent or in Combination With Chemotherapy:
* Weekly: Administer initial dose of 400 mg/m2 as a 120-minute intravenous infusion, and subsequent doses of 250 mg/m2 infused over 60 minutes once weekly.
* Biweekly: Administer 500 mg/m2 as a 120-minute intravenous infusion every two weeks.
* Complete ERBITUX administration 1 hour prior to chemotherapy. Continue treatment until disease progression or unacceptable toxicity.

* See full prescribing information for dosage adjustments for adverse reactions.

Get Your Patient on Erbitux

Find restrictionsSee step therapiesCompare coverage options

Erbitux Prescribing Information

Contact Medical Science Liaison

Report Adverse Event

Erbitux Prior Authorization Resources

Most recent state uniform prior authorization forms

Verified: Sep 24, 2024Arizona - Uniform Prior Authorization Form

Verified: Sep 24, 2024Colorado - Uniform Prior Authorization Form

Verified: Sep 24, 2024Hawaii - Uniform Prior Authorization Form

Verified: Sep 24, 2024Illinois - Uniform Prior Authorization Form

Verified: Sep 24, 2024Indiana - Uniform Prior Authorization Form

Verified: Sep 24, 2024Louisiana - Uniform Prior Authorization Form

Verified: Sep 24, 2024Minnesota - Uniform Prior Authorization Form

Verified: Sep 24, 2024New Hampshire - Uniform Prior Authorization Form

Verified: Sep 24, 2024New Mexico - Uniform Prior Authorization Form

Verified: Sep 24, 2024Oregon - Uniform Prior Authorization Form

Verified: Sep 24, 2024Texas - Uniform Prior Authorization Form

Verified: Oct 05, 2024Washington - Uniform Prior Authorization Form

Verified: Oct 05, 2024Wisconsin - Uniform Prior Authorization Form

Coverage Authorization Appeals (First-Level)

Coverage Authorization Appeals (Second Level)

Denied Claims Checklist

First-Level Medicare Review Letter

Complete Letter of Medical Necessity

Second-Level Medicare Review Letter

Benefits investigation

Lilly Oncology Support - Erbitux Enrollment Form

Lilly Oncology Support - Erbitux Enrollment Form (Online)

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information

Erbitux Financial Assistance Options

Copay savings program

Lilly Oncology Support - Erbitux Enrollment Form

Enroll in Patient Savings Program

Lilly Oncology Support - Erbitux Enrollment Form (Online)

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Foundation programs

Lilly Cares Foundation

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and copays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.